Background: Cancer immunotherapy is a promising strategy for cancer treatment. In this strategy， the immune system is triggered to destroy cancer cells. IL-2 is an important factor in passive cancer immunotherapy that helps modulating some important immune functions. One of the IL-2 limitations is low serum half-life; therefore， repetitive high doses of the injections are required to maintain effective concentrations. High-dose IL-2 therapy results in severe side effects; thus， improvement of its serum half-life would provide therapeutic benefits.
Background: Cancer immunotherapy is a promising strategy for cancer treatment. In this strategy， the immune system is triggered to destroy cancer cells. IL-2 is an important factor in passive cancer immunotherapy that helps modulating some important immune functions. One of the IL-2 limitations is low serum half-life; therefore， repetitive high doses of the injections are required to maintain effective concentrations. High-dose IL-2 therapy results in severe side effects; thus， improvement of its serum half-life would provide therapeutic benefits.
